Security
Rani Therapeutics Holdings, Inc. Class A Common Stock · RANI
RANINASDAQCommon stockCurrentCIK 1856725Updated Oct 6, 2026
RANI price & chart
Loading TradingView…
NASDAQ:RANI on TradingView ↗About the company
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® Capsule™, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® Capsule technology.
In the news
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
SCHEDULE 13G/A - filed by VANGUARD CAPITAL MANAGEMENT LLC regarding Rani Therapeutics Holdings, Inc.
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 10,139,000Source | 43,540,000Source | 60,843,000Source | 16,898,000Source | 43,726,000Source | 51,879,000Source | 24,125,000Source | 53,512,000Source | 58,621,000Source | 36,634,000Source | 57,916,000Source | 108,027,000Source |
| Property, Plant and Equipment, NetUSD | 922,000Source | 5,496,000Source | 525,000Source | 1,144,000Source | 5,695,000Source | 601,000Source | 1,348,000Source | 5,905,000Source | 736,000Source | 1,548,000Source | 6,105,000Source | 6,038,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,144,000Source | 4,277,000Source | 4,868,000Source | 10,216,000Source | 4,514,000Source | 9,644,000Source | 10,111,000Source | 6,877,000Source | 18,618,000Source | 3,762,000Source | 5,864,000Source | 27,007,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 2,042,000Source | — | — | 2,042,000Source | 600,000Source | — | 2,042,000Source | — | — | — |
| Assets, CurrentUSD | 4,955,000Source | 32,371,000Source | 56,523,000Source | 11,073,000Source | 32,034,000Source | 47,091,000Source | 17,783,000Source | 41,390,000Source | 53,321,000Source | 29,744,000Source | 50,847,000Source | 100,924,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,017,000Source | 5,427,000Source | 3,549,000Source | 4,388,000Source | 5,751,000Source | 3,941,000Source | 4,748,000Source | 5,971,000Source | 4,318,000Source | 5,096,000Source | 718,000Source | 1,065,000Source |
| Other Assets, NoncurrentUSD | 245,000Source | 246,000Source | 246,000Source | 293,000Source | 246,000Source | 246,000Source | 246,000Source | 246,000Source | 246,000Source | 246,000Source | 246,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 22,112,000Source | 37,765,000Source | 12,858,000Source | 26,051,000Source | 38,176,000Source | 16,336,000Source | 29,474,000Source | 38,977,000Source | 17,109,000Source | 33,141,000Source | 32,473,000Source | 34,023,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Additional Paid in CapitalUSD | 114,406,000Source | 97,067,000Source | 186,255,000Source | 111,280,000Source | 90,012,000Source | 168,015,000Source | 107,108,000Source | 87,776,000Source | 165,578,000Source | 104,889,000Source | 85,762,000Source | 75,842,000Source |
| Retained Earnings (Accumulated Deficit)USD | -122,275,000Source | -93,960,000Source | -147,004,000Source | -116,863,000Source | -87,177,000Source | -139,613,000Source | -110,171,000Source | -80,372,000Source | -132,580,000Source | -102,907,000Source | -72,889,000Source | -38,919,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 3,000Source | 8,000Source | -30,000Source | 3,000Source | -5,000Source | -8,000Source | 2,000Source | -11,000Source | 1,000Source | 5,000Source | -12,000Source | -73,000Source |
| Stockholders' Equity Attributable to ParentUSD | -7,860,000Source | 3,120,000Source | 39,234,000Source | -5,575,000Source | 2,835,000Source | 28,405,000Source | -3,056,000Source | 7,398,000Source | 33,010,000Source | 1,992,000Source | 12,866,000Source | 36,855,000Source |
| Liabilities and EquityUSD | 10,139,000Source | 43,540,000Source | 60,843,000Source | 16,898,000Source | 43,726,000Source | 51,879,000Source | 24,125,000Source | 53,512,000Source | 58,621,000Source | 36,634,000Source | 57,916,000Source | 108,027,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 19,144,000Source | 20,211,000Source | 10,638,000Source | 20,623,000Source | 16,581,000Source | 13,855,000Source | 20,130,000Source | 13,375,000Source | 12,669,000Source | 19,891,000Source | 7,989,000Source | 4,815,000Source |
| Operating Lease, Liability, CurrentUSD | 1,049,000Source | 1,410,000Source | 1,329,000Source | 1,189,000Source | 1,363,000Source | 1,460,000Source | 1,325,000Source | 1,222,000Source | 1,586,000Source | 1,459,000Source | 718,000Source | 1,006,000Source |
| Accounts Payable, CurrentUSD | 2,467,000Source | 1,566,000Source | 1,049,000Source | 1,798,000Source | 506,000Source | 858,000Source | 1,520,000Source | 806,000Source | 309,000Source | 1,359,000Source | 648,000Source | 1,460,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,968,000Source | 4,017,000Source | 2,220,000Source | 3,199,000Source | 4,388,000Source | 2,481,000Source | 3,423,000Source | 4,749,000Source | 2,732,000Source | 3,637,000Source | 0Source | 59,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -4,113,000Source | 2,655,000Source | 8,751,000Source | -3,578,000Source | 2,715,000Source | 7,138,000Source | -2,293,000Source | 7,137,000Source | 8,502,000Source | 1,501,000Source | 12,577,000Source | 37,149,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 2,296,000Source |
| Deferred Revenue, CurrentUSD | — | — | 5,123,000Source | — | — | 6,831,000Source | — | — | 6,831,000Source | — | — | — |
| Deferred Revenue, NoncurrentUSD | — | — | 0Source | — | — | 0Source | — | — | 1,708,000Source | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 13,537,000Source | 14,768,000Source | — | 15,000,000Source | 12,290,000Source | — | 15,000,000Source | 8,586,000Source | 0Source | 15,000,000Source | 4,897,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 0Source | 13,537,000Source | — | 2,229,000Source | 17,207,000Source | — | 5,921,000Source | 20,853,000Source | 0Source | 9,613,000Source | 24,484,000Source | 29,149,000Source |
| Long-term Debt, Excluding Current Maturities | —Source | —Source | — | —Source | —Source | — | —Source | —Source | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -7,914,000Source | -12,722,000Source | -8,421,000Source | -11,224,000Source | -8,015,000Source | -12,738,000Source | -40,950,000Source | -56,584,000Source | -67,883,000Source | -63,344,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,084,000Source | 3,925,000Source | 11,798,000Source | 16,031,000Source | 19,008,000Source | 15,782,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 0Source | 600,000Source | 2,042,000Source | — | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,497,000Source | -8,149,000Source | -18,714,000Source | -35,496,000Source | -51,236,000Source | -46,515,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -2,450,000Source | 18,229,000Source | -7,030,000Source | 19,809,000Source | 29,860,000Source | -72,436,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 15,000Source | 51,000Source | 88,000Source | 268,000Source | 1,229,000Source | 1,619,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 32,000Source | 23,000Source | 59,000Source | 47,000Source | 162,000Source | 626,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -27,000Source | -3,731,000Source | 40,300,000Source | 13,585,000Source | 233,000Source | 29,005,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 0Source | 3,750,000Source | 20,722,000Source | 5,000,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -8,974,000Source | 6,349,000Source | 14,556,000Source | -2,102,000Source | -21,143,000Source | -89,946,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 4,644,000Source | 4,777,000Source | 5,068,000Source | 10,716,000Source | 9,844,000Source | 10,611,000Source | 18,818,000Source | 4,262,000Source | 6,364,000Source | 27,507,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 2,121,000Source | 4,112,000Source | 4,182,000Source | 48,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 35,000Source | 730,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 2,084,000Source | 3,925,000Source | 11,798,000Source | 16,031,000Source | 19,008,000Source | 15,782,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 0Source | 58,000Source | 207,000Source | 232,000Source | 232,000Source | 77,000Source |
| DepreciationUSD | — | — | — | — | 200,000Source | 200,000Source | 200,000Source | 300,000Source | 900,000Source | 1,000,000Source | 800,000Source | 500,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | -65,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -576,000Source | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 4,036,000Source | 5,627,000Source | 5,519,000Source | 5,000,000Source | 4,886,000Source | 5,615,000Source | 19,738,000Source | 23,946,000Source | 26,475,000Source | 26,844,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 70,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,412,000Source | -6,783,000Source | -7,391,000Source | -6,692,000Source | -7,033,000Source | -7,264,000Source | -29,673,000Source | -30,018,000Source | -33,970,000Source | -30,588,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -2,502,000Source | -5,939,000Source | -1,030,000Source | -4,532,000Source | -982,000Source | -5,474,000Source | -11,277,000Source | -26,566,000Source | -33,913,000Source | -32,756,000Source |
| Operating ExpensesUSD | — | — | 7,257,000Source | 11,799,000Source | 10,536,000Source | 10,505,000Source | 10,047,000Source | 12,185,000Source | 39,943,000Source | 54,342,000Source | 66,099,000Source | 63,451,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 10,000Source | 51,000Source | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | -11,000Source | 0Source | -6,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 1,708,000Source | 0Source | 1,708,000Source | 172,000Source | 1,633,000Source | 1,028,000Source | — | 0Source |
| Operating Income (Loss)USD | — | — | -7,257,000Source | -11,799,000Source | -8,828,000Source | -10,505,000Source | -8,339,000Source | -12,013,000Source | -38,310,000Source | -53,314,000Source | -66,099,000Source | -63,451,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -67,883,000Source | -63,274,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 70,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -2,502,000Source | -5,939,000Source | -1,030,000Source | -4,532,000Source | -982,000Source | -5,474,000Source | -11,277,000Source | -26,566,000Source | -33,913,000Source | -32,756,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,412,000Source | -6,783,000Source | -7,391,000Source | -6,692,000Source | -7,033,000Source | -7,264,000Source | -29,673,000Source | -30,018,000Source | -33,970,000Source | -30,588,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.12Source | -0.24Source | -0.04Source | -0.18Source | -0.04Source | -0.22Source | -0.45Source | -1.05Source | -1.33Source | -1.28Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.12Source | -0.24Source | -0.04Source | -0.18Source | -0.04Source | -0.22Source | -0.45Source | -1.05Source | -1.33Source | -1.28Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 46,444,000Source | 28,836,000Source | 187,168,000Source | 36,542,000Source | 179,996,000Source | 33,440,000Source | 66,138Source | 28,476Source | 25,505Source | 23,817Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 46,444,000Source | 28,836,000Source | 187,168,000Source | 36,542,000Source | 179,996,000Source | 33,440,000Source | 66,138Source | 28,476Source | 25,505Source | 23,817Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 70,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 161,000Source | 251,000Source | 900,000Source | 1,028,000Source | 822,000Source | 548,000Source |
| General and Administrative ExpenseUSD | — | — | 4,036,000Source | 5,627,000Source | 5,519,000Source | 5,000,000Source | 4,886,000Source | 5,615,000Source | 19,738,000Source | 23,946,000Source | 26,475,000Source | 26,844,000Source |
| Interest and Other IncomeUSD | — | — | 68,000Source | 414,000Source | 415,000Source | 158,000Source | 412,000Source | 218,000Source | 827,000Source | 1,763,000Source | 3,301,000Source | 1,248,000Source |
| Interest ExpenseUSD | — | — | 725,000Source | 1,337,000Source | 8,000Source | 877,000Source | 88,000Source | 943,000Source | 2,891,000Source | 5,033,000Source | 5,085,000Source | 1,071,000Source |
| Operating ExpensesUSD | — | — | 7,257,000Source | 11,799,000Source | 10,536,000Source | 10,505,000Source | 10,047,000Source | 12,185,000Source | 39,943,000Source | 54,342,000Source | 66,099,000Source | 63,451,000Source |
| Research and Development ExpenseUSD | — | — | 3,221,000Source | 6,172,000Source | 5,017,000Source | 5,505,000Source | 5,161,000Source | 6,570,000Source | 20,205,000Source | 26,682,000Source | 39,624,000Source | 36,607,000Source |
Filing attachments
rani-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 rani-ex99_1.htm EX-99.1 EX-99.1 Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update ~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026~ ~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~ ~Completed a $20 million registered direc…
Read attachment ↗d312913dex41.htm · 8-K · 2026-05-27
EX-4.1 2 d312913dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT RANI THERAPEUTICS HOLDINGS, INC. Warrant Shares: [_______] Original Issue Date: May 27, 2026 ──────────────────────────────────────────────────────────────────── THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_____________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condi…
Read attachment ↗rani-ex99_1.htm · 8-K · 2026-05-15
EX-99.1 2 rani-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen - Appointed Alireza Javadi, Ph. D. as Chief Technical Officer - Appointed Jesper Høiland as Head of Strategy and Dr. Sara Kenkare-Mitra as a Strategic Advisor - SAN JOSE, Calif., May 1…
Read attachment ↗rani-ex99_1.htm · 8-K · 2026-03-26
EX-99.1 2 rani-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus - - Announced preclinical data demonstrating su…
Read attachment ↗